Phase 3RecruitingINTERVENTIONAL
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
ClinicalTrials.gov · NCT07653477 · Registry updated: 2026-09-14
- Condition / research focus
- Type 2 Diabetes
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2026-09-07. Completion: 2028-02-29 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- UBT251 Injection 2.0 mg group (drug)
- UBT251 Injection 4.0 mg group (drug)
- UBT251 Injection 6.0 mg group (drug)
- Semaglutide Injection (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.